Tag: pertuzumab market forecast

Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the perjeta (pertuzumab) market grown in recent years?

Recent years have seen a swift expansion in the market size for Perjeta (pertuzumab). The market size is projected to increase from $935.92 million in 2024 to reach $1,084.80 million in 2025, with a compelling compound annual growth rate (CAGR) of 15.9%. Factors contributing to this growth during the historical period include a rise in the adoption of Perjeta in oncology, an uptick in the demand for ADCs, a preference for targeted and less damaging treatments, an enhanced level of inorganic growth, as well as an increased demand for targeted and individualized medicine.

How is the perjeta (pertuzumab) market size expected to evolve during the forecast period?

It is anticipated that the market size for Perjeta (pertuzumab) will experience a swift expansion in the upcoming years, reaching up to $1,932.66 million by the year 2029 with a compound annual growth rate (CAGR) of 15.5%. The acceleration in the market during the forecast period can be owed to the increasing cases of breast cancer, a growing interest in ADCs for hematologic malignancies, a rise in cancer occurrences, unfulfilled healthcare needs related to cancer, and an uptick in pharmaceutical research and development for cancer immunotherapy. Noteworthy trends for the forecast period comprise of the use of biosimilars in cancer treatment, the creation of biosimilars and generics, breakthroughs in medication formulations, progressions in cancer immunotherapy investigation, and the rise in prominence of combination therapies.

Get your perjeta (pertuzumab) market report here!

https://www.thebusinessresearchcompany.com/report/perjeta-pertuzumab-global-market-report

Which key drivers are propelling the perjeta (pertuzumab) market’s growth?

The escalating occurrence of breast cancer is predicted to drive the growth of the Perjeta (pertuzumab) market in the future. This disease, characterized by the formation of harmful cells in breast tissue, often stems from the ducts or lobules. Lifestyle alterations such as increased obesity and sedentary behavior, along with enhanced early detection via extensive screening programs, contribute to the growing incidence of breast cancer. Perjeta (pertuzumab), typically paired with trastuzumab and chemotherapy, targets the HER2 receptor to treat HER2-positive breast cancer, thereby enhancing treatment results. For example, Ray of Light Wales, a non-profit charity based in the UK, reported in October 2023 that the population of people in the UK post-breast cancer diagnosis is supposed to be around 600,000, with a forecast to spike to 1.2 million by 2030. Consequently, the increasing occurrence of breast cancer is fueling the growth of the herceptin biosimilars market.

What are the market segments in the perjeta (pertuzumab) industry?

The perjeta (pertuzumab)market covered in this report is segmented –

1) By Type: Human source; Animal source

2) By Product: Monoclonal Antibody; Biologic Drug

3) By Indication: Early Breast Cancer; Metastatic Breast Cancer

4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19917&type=smp

Which leading companies are shaping the growth of the perjeta (pertuzumab) market?

Major companies operating in the perjeta (pertuzumab) market include Roche Holding AG

What key trends are currently impacting the perjeta (pertuzumab) market’s development?

A crucial trend in the Perjeta (pertuzumab) marketplace is the concentration on inventing technologically superior solutions like subcutaneous combination therapies, ultimately enhancing the outcomes of patients and the convenience of treatments. The term subcutaneous combination therapies pertains to treatment approaches where numerous medications are merged into a single subcutaneous injection (given underneath the skin) to cure a specific illness. For instance, in November 2023, Chugai Pharmaceutical Co., Ltd., a corporation based in Japan, introduced Phesgo, a revolutionary treatment for subcutaneous use for HER2-positive breast cancer and recurrent or advanced HER2-positive colorectal cancer. This novel subcutaneous administration treatment amalgamates the monoclonal antibodies pertuzumab and trastuzumab with vorhyaluronidase alfa, enabling application in a mere 5 to 8 minutes, marking a significant dip in time as compared to traditional intravenous infusions. Phesgo is indicated for patients having advanced or recurrent HER2-positive colorectal cancer and stands as the pioneer subcutaneous alternative for this condition.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19917

Which geographic areas are influencing the growth of the perjeta (pertuzumab) market?

North America was the largest region in the perjeta (pertuzumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the perjeta (pertuzumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Metastatic Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/metastatic-cancer-drugs-global-market-report

Gastric Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Alpha Glucosidase Inhibitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/alpha-glucosidase-inhibitors-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Growth Potential of the Perjeta (Pertuzumab) Market, and How Will It Perform by 2034?

The market size for pertuzumab (Perjeta) has seen a quick expansion in the recent past. The growth is anticipated to rise from $935.92 million in 2024 to $1,084.80 million in 2025, representing a compound annual growth rate (CAGR) of 15.9%. The expansion during the previous period is due to factors such as larger acceptance in the field of oncology, increased demand for antibody-drug conjugates (ADCs), preference for targeted and less harmful treatments, enhanced inorganic growth, and a growing demand for targeted and personalized medication.

The market for perjeta (pertuzumab) is projected to experience swift expansion in the coming years, ballooning to $1,932.66 million in 2029 with a compound annual growth rate (CAGR) of 15.5%. Factors such as the increasing instances of breast cancer, growing interest in ADCs for hematological malignancies, the escalating rate of cancer, unfulfilled medical necessities, and amplified efforts in pharmaceutical research and development for cancer immunotherapy are expected to attribute to this growth in the forecasted period. Noteworthy trends during this period include the adoption of biosimilars in cancer treatment, the creation of generics and biosimilars, drug formulation innovations, advancements in cancer immunotherapy studies, and the rising prominence of combination therapies.

Which Drivers Are Expected to Have the Greatest Impact on the Perjeta (Pertuzumab) Market’s Growth?

The anticipated escalation in breast cancer cases will likely spur the expansion of the Perjeta (pertuzumab) market. This malady characterized by the formation of destructive cells in mammary tissue often stems from the ducts or lobules. Factors such as modification in living habits including sedentariness and obesity, along with enhanced early revelation due to comprehensive screening procedures can be attributed to this increment. Comprising an essential component of HER2-positive breast cancer treatment, Perjeta (pertuzumab) is pivotal in targeting HER2 receptor and is commonly amalgamated with trastuzumab and chemotherapy to augment the efficacy of treatment. Ray of Light Wales, a non-profit charity in the UK, anticipated in October 2023, that the count of citizens in the UK surviving post breast cancer diagnosis was predicted at 600,000 and is forecasted to surge to 1.2 million by 2030. Consequently, this growing occurrence of breast cancer propels the herceptin biosimilars market’s growth.

Get Your Free Sample of the Global Perjeta (Pertuzumab) Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=19917&type=smp

Who Are the Major Companies Shaping the Competitive Landscape of the Perjeta (Pertuzumab) Market?

Major companies operating in the perjeta (pertuzumab) market include Roche Holding AG

What Are the Key Emerging Trends in the Perjeta (Pertuzumab) Market for the Next Decade?

A notable progression in the Perjeta (pertuzumab) marketplace is the emphasis on creating cutting-edge solutions such as subcutaneous combination treatments, designed to enhance patient results and convenience of treatment. Subcutaneous combination therapies involve the fusion of more than one drug in one subcutaneous injection (injected below the skin) for ailment treatment. For example, in November 2023, Chugai Pharmaceutical Co., Ltd., a firm specialized in pharmaceuticals based in Japan, introduced Phesgo, a distinct combination treatment for HER2-positive breast cancer and advanced recurring HER2-positive colorectal cancer, administered subcutaneously. This innovative solution integrates the monoclonal antibodies pertuzumab and trastuzumab with vorhyaluronidase alfa, offering an administration time of just 5 to 8 minutes, remarkably lessening the time relative to traditional intravenous infusions. Phesgo is prescribed for patients with advanced recurrent HER2-positive colorectal cancer and is the pioneering subcutaneous option for this disease.

Get Instant Access to the Global Perjeta (Pertuzumab) Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/perjeta-pertuzumab-global-market-report

What Are the Core Categories and Segments in the Perjeta (Pertuzumab) Market Driving Demand and Growth?

The perjeta (pertuzumab)market covered in this report is segmented –

1) By Type: Human source; Animal source

2) By Product: Monoclonal Antibody; Biologic Drug

3) By Indication: Early Breast Cancer; Metastatic Breast Cancer

4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Which Regions Are Making a Mark in the Perjeta (Pertuzumab) Market Growth?

North America was the largest region in the perjeta (pertuzumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the perjeta (pertuzumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

How Is the Perjeta (Pertuzumab) Market Categorized and Defined in the Industry?

Perjeta (pertuzumab) is a targeted therapy used in the treatment of certain types of breast cancer. It is a monoclonal antibody that specifically binds to the human epidermal growth factor receptor 2 (HER2), a protein that promotes the growth of cancer cells in HER2-positive breast cancer.

Browse Through More Similar Reports By The Business Research Company:

Metastatic Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/metastatic-cancer-drugs-global-market-report

Gastric Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Alpha Glucosidase Inhibitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/alpha-glucosidase-inhibitors-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: